Introduction
Tirzepatide is a dual GIP and GLP-1 receptor agonist widely discussed in metabolic clinical research literature. Catalog research material from VialVibes is Research Use Only and is not an approved drug product.
Chemical and structural summary
Dual incretin-pathway peptide research material. CAS 2023788-19-2 commonly listed. Confirm lot CoA for identity and purity.
| Catalog name | Tirzepatide |
|---|---|
| Category | Metabolic Research |
| CAS | 2023788-19-2 |
| Molecular weight note | About 4813.5 g/mol (reference) |
| Documentation | Lot-specific CoA available on request |
Research history and background
Dual agonism at GIP and GLP-1 receptors has been investigated in clinical development programs (e.g., SURPASS and SURMOUNT series) for metabolic disease endpoints under regulated pharmaceutical pathways. Those programs are distinct from RUO laboratory supply.
Areas investigated in laboratory and preclinical research
The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.
- Dual GIP/GLP-1 receptor pharmacology research
- Metabolic model systems informed by dual-agonist literature
- Comparative incretin research alongside single GLP-1 agonists
Mechanisms discussed in the literature
Literature describes simultaneous engagement of GIP and GLP-1 receptors with effects on glycemic and body-weight endpoints in clinical studies of the pharmaceutical product. Mechanistic summaries are for scientific literacy only and do not authorize human use of research reagents.
Key published studies and reviews
Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.
Known limitations and evidence gaps
Approved pharmaceutical tirzepatide products are regulated medicines. Research materials sold RUO are not interchangeable with them. Clinical efficacy results do not constitute claims for laboratory reagents.
Laboratory handling notes
General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.
- Storage and stability of lyophilized peptides
- Reconstitution best practices for laboratory use
- Reconstitution calculator (concentration and aliquot volume math)
- How to read a Certificate of Analysis
Regulatory status note
Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.